Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • CTI Biopharma

    - PMLiVE

    Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

    C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

    - PMLiVE

    Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

    Approximately 7,700 people in England are living with the genetic bleeding disorder

    - PMLiVE

    Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

    The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

    - PMLiVE

    Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study

    There are currently no treatments that target the underlying cause of C3G or IC-MPGN

    - PMLiVE

    Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

    The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

    - PMLiVE

    Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH

    The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria

    - PMLiVE

    Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

    The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

    - PMLiVE

    Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP

    Immune thrombocytopenia is estimated to affect up to 100 people per million

    - PMLiVE

    Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition

    The deal includes an investigational therapy being evaluated in myelofibrosis

    - PMLiVE

    GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia

    The rare blood cancer affects approximately one in every 500,000 people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links